Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169437 · ClinicalTrials.gov registry record · Phase 2
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
A Phase 2 study, sponsored by Tempus AI.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05169437: Clinical Trial Phase 2 study, sponsored by Tempus AI.
NCT05169437 is a Phase 2 study that was terminated before completion, run by Tempus AI. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05169437, a Phase 2 study, was terminated before completion, sponsored by Tempus AI.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Primary Outcome
To evaluate overall response rate (ORR) as assessed by Independent Central Review (ICR) using RECIST v1.1
Interventions
- DRUG Niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 2 |
Why NCT05169437 stopped before completion
NCT05169437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Niraparib is the first listed.
NCT05169437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05169437 about?
NCT05169437 is a clinical study titled "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors". The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
What is the current status of trial NCT05169437?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-03-15. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT05169437?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT05169437?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05169437's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI